ProteoNic licenses its 2G UNic technology to Ginkgo Bioworks for a BARDA-backed consortium to boost fast, cost‑effective mAb production against filoviruses ... .
With BARDA (valued up to USD 51 m) for development through FDA approval... How is BARDA's collaboration accelerating Orexo's development of rescue therapies? ... Orexo NewsRelease OX390 And BARDA PartnershipInterview With Ed Kim MD CMODec 5 2025.
This pivotal collaboration, which represents Rafa's second major contract with BARDA, addresses an urgent global need ... BARDA and Rafa are Collaborating on a Comprehensive DevelopmentApproach.
TIVIC SECURES BARDA MEETING ... The process enables BARDA to evaluate technology readiness, understand manufacturing and approval requirements, and identify potential pathways to funding and purchasing ... More About BARDA.
$100M prize competition announced by BARDA and Start2 Group to develop innovative broad-spectrum antiviral therapies Post this. "We are honored to partner with BARDA to lead this prize competition that ...
"We are honored to work with BARDA and our BioMaP-Consortium partners to bring these and other innovations to the domestic production of mAb-based medical countermeasures ... This BARDA-supported ...